nach oben

Erschienen in:

19.05.2021 | COVID-19 | Original Paper

Resilience, Anxiety, Stress, and Substance Use Patterns During COVID-19 Pandemic in the Miami Adult Studies on HIV (MASH) Cohort

verfasst von: Janet Diaz-Martinez, Javier A. Tamargo, Ivan Delgado-Enciso, Qingyun Liu, Leonardo Acuña, Eduardo Laverde, Manuel A. Barbieri, Mary Jo Trepka, Adriana Campa, Suzanne Siminski, Pamina M. Gorbach, Marianna K. Baum

Erschienen in: AIDS and Behavior | Ausgabe 11/2021

Einloggen, um Zugang zu erhalten

Abstract

We evaluated mental health and substance use during the COVID-19 pandemic in 196 participants from the Miami Adult Studies on HIV (MASH) Cohort. A survey was administered between July–August of 2020, including validated measures of resilience and anxiety, a scale to measure COVID-19-related worry, and self-reported substance use. Compared to HIV-uninfected participants (n = 80), those living with HIV (n = 116) reported fewer anxiety symptoms, less COVID-19-related worry, and higher resilience. Those with more anxiety symptoms and lower resilience engaged in more frequent alcohol consumption, binge drinking, and cocaine use. Alcohol misuse was more common among HIV-uninfected participants. Cocaine use was reported by 21% fewer participants during the pandemic compared with 7.3 ± 1.5 months earlier. Possibly due to their experiences with HIV, PLWH responded with higher resilience and reduced worry and anxiety to the adversities brought by the COVID-19 pandemic.

World Health Organization. Mental health and psychosocial considerations during the COVID-19 outbreak. World Health Organization; 2020. Report No.: WHO/2019-nCoV/MentalHealth/2020.1. https://www.who.int/publications/i/item/WHO-2019-nCoV-MentalHealth-2020.1.

Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 2020;16(1):57. https://doi.org/10.1186/s12992-020-00589-w.CrossRefPubMedPubMedCentral

Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24(8):2244–9. https://doi.org/10.1007/s10461-020-02871-9.CrossRefPubMedPubMedCentral

Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4): https://doi.org/10.1016/S2215-0366(20)30090-0.CrossRefPubMedPubMedCentral

Pellowski JA, Kalichman SC, Matthews KA, Adler N. A pandemic of the poor: social disadvantage and the U.S. HIV epidemic. Am Psychol. 2013;68(4):197–209. https://doi.org/10.1037/a0032694.CrossRefPubMedPubMedCentral

Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. Subst Abuse Treat Prev Policy. 2019;14(1):52. https://doi.org/10.1186/s13011-019-0240-3.CrossRefPubMedPubMedCentral

Gallant J, Hsue PY, Shreay S, Meyer N. Comorbidities among US patients with prevalent HIV infection-a trend analysis. J Infect Dis. 2017;216(12):1525–33. https://doi.org/10.1093/infdis/jix518.CrossRefPubMed

Yang HY, Beymer MR, Suen SC. Chronic disease onset among people living with HIV and AIDS in a large private insurance claims dataset. Sci Rep. 2019;9(1):18514. https://doi.org/10.1038/s41598-019-54969-3.CrossRefPubMedPubMedCentral

Amin P, Douaihy A. Substance use disorders in people living with human immunodeficiency virus/AIDS. Nurs Clin N Am. 2018;53(1):57. https://doi.org/10.1016/j.cnur.2017.10.007.CrossRef

10.

De Santis JP, Florom-Smith A, Vermeesch A, Barroso S, DeLeon DA. Motivation, management, and mastery: a theory of resilience in the context of HIV infection. J Am Psychiatr Nurses Assoc. 2013;19(1):36–46. https://doi.org/10.1177/1078390312474096.CrossRefPubMedPubMedCentral

11.

Norris FH, Tracy M, Galea S. Looking for resilience: understanding the longitudinal trajectories of responses to stress. Soc Sci Med (1982). 2009;68(12):2190–8. https://doi.org/10.1016/j.socscimed.2009.03.043.CrossRef

12.

Windle G. What is resilience? A review and concept analysis. Rev Clin Gerontol. 2010;21(2):152–69. https://doi.org/10.1017/s0959259810000420.CrossRef

13.

Diehl M, Hay EL, Chui H. Personal risk and resilience factors in the context of daily stress. Annu Rev Gerontol Geriatr. 2012;32(1):251–74. https://doi.org/10.1891/0198-8794.32.251.CrossRefPubMedPubMedCentral

14.

Zhang J, Yang Z, Wang X, Li J, Dong LL, Wang FS, et al. The relationship between resilience, anxiety and depression among patients with mild symptoms of COVID-19 in China: a cross-sectional study. J Clin Nurs. 2020;29(21–22):4020–9. https://doi.org/10.1111/jocn.15425.CrossRefPubMed

15.

Zaami S, Marinelli E, Vari MR. New trends of substance abuse during COVID-19 pandemic: an international perspective. Front Psychiatry. 2020;11:700. https://doi.org/10.3389/fpsyt.2020.00700.CrossRefPubMedPubMedCentral

16.

NIDA. COVID-19: Potential implications for individuals with substance use disorders. National Institute on Drug Abuse website. https://www.drugabuse.gov/about-nida/noras-blog/2020/04/covid-19-potential-implications-individuals-substance-use-disorders. April 6, 2020.

17.

Centers for Disease Control and Prevention. HIV surveillance report, 2018 (Updated). 2020. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

18.

Lieb S, Rosenberg R, Arons P, Malow RM, Liberti TM, Maddox LM, et al. Age shift in patterns of injection drug use among the HIV/AIDS population in Miami-Dade County, Florida. Subst Use Misuse. 2006;41(10–12):1623–35. https://doi.org/10.1080/10826080600847985.CrossRefPubMed

19.

Bartholomew TS, Onugha J, Bullock C, Scaramutti C, Patel H, Forrest DW, et al. Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL. Harm Reduct J. 2020;17(1):40. https://doi.org/10.1186/s12954-020-00385-0.CrossRefPubMedPubMedCentral

20.

Zarini G, Sales Martinez S, Campa A, Sherman K, Tamargo J, Hernandez Boyer J, et al. Sex differences, cocaine use, and liver fibrosis among African Americans in the Miami Adult Studies on HIV Cohort. J Womens Health. 2020;29(9):1176–83. https://doi.org/10.1089/jwh.2019.7954.CrossRef

21.

Blanco JL, Ambrosioni J, Garcia F, Martinez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314–6. https://doi.org/10.1016/S2352-3018(20)30111-9.CrossRefPubMedPubMedCentral

22.

Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D, et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa579.CrossRefPubMed

23.

Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7. https://doi.org/10.1001/archinte.166.10.1092.CrossRefPubMed

24.

Ruiz MA, Zamorano E, Garcia-Campayo J, Pardo A, Freire O, Rejas J. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disorders. 2011;128(3):277–86. https://doi.org/10.1016/j.jad.2010.07.010.CrossRefPubMed

25.

Smith BW, Dalen J, Wiggins K, Tooley E, Christopher P, Bernard J. The brief resilience scale: assessing the ability to bounce back. Int J Behav Med. 2008;15(3):194–200. https://doi.org/10.1080/10705500802222972.CrossRefPubMed

26.

Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health Qual Life Outcomes. 2011;9:8. https://doi.org/10.1186/1477-7525-9-8.CrossRefPubMedPubMedCentral

27.

Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158(16):1789–95. https://doi.org/10.1001/archinte.158.16.1789.CrossRefPubMed

28.

Kantamneni N. The impact of the COVID-19 pandemic on marginalized populations in the United States: a research agenda. J Vocat Behav. 2020;119:103439. https://doi.org/10.1016/j.jvb.2020.103439.CrossRefPubMedPubMedCentral

29.

Beer L, Tie Y, Padilla M, Shouse RL, Medical Monitoring P. Generalized anxiety disorder symptoms among persons with diagnosed HIV in the United States. AIDS. 2019;33(11):1781–7. https://doi.org/10.1097/QAD.0000000000002286.CrossRefPubMed

30.

Twenge JM, Joiner TEUS. Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID-19 pandemic. Depress Anxiety. 2020;37(10):954–6. https://doi.org/10.1002/da.23077.CrossRefPubMed

31.

McGowan JA, Sherr L, Rodger AJ, Fisher M, Miners A, Anderson J, et al. Age, time living with diagnosed HIV infection, and self-rated health. HIV Med. 2017;18(2):89–103. https://doi.org/10.1111/hiv.12398.CrossRefPubMed

32.

Lyons A, Heywood W. Collective resilience as a protective factor for the mental health and well-being of HIV-positive gay men. Psychol Sex Orientat Gender Divers. 2016;3(4):473–9. https://doi.org/10.1037/sgd0000197.CrossRef

33.

Emlet CA, Shiu C, Kim HJ, Fredriksen-Goldsen K. Bouncing back: resilience and mastery among HIV-positive older gay and bisexual men. The Gerontologist. 2017;57(suppl 1):S40–9. https://doi.org/10.1093/geront/gnw171.CrossRefPubMedPubMedCentral

34.

Medical Examiners Commission. Drugs identified in deceased persons by Florida Medical Examiners. Florida Department of Law Enforcement; 2020. https://www.fdle.state.fl.us/MEC/Publications-and-Forms/Documents/Drugs-in-Deceased-Persons/2019-Interim-Drug-Report-FINAL.aspx.

35.

Crane HM, McCaul ME, Chander G, Hutton H, Nance RM, Delaney JAC, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017;21(7):1914–25. https://doi.org/10.1007/s10461-017-1740-7.CrossRefPubMedPubMedCentral

36.

Ovalle D. Cocaine, meth and weed prices have skyrocketed in Miami: Here’s why. Miami Herald; 2020. https://amp.miamiherald.com/news/local/crime/article246014720.html. Accessed 2 Oct 2020.

37.

United Nations Office On Drugs And Crime. COVID-19 and the drug supply chain: from production and trafficking to use. Research and Trend Analysis Branch & UNODC Global Research Network; 2020. https://www.unodc.org/documents/data-and-analysis/covid/Covid-19-and-drug-supply-chain-Mai2020.pdf.

38.

Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Alcohol Res Health. 2006;29(2):107–20.PubMedCentral

39.

Pettinati HM, O’Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23–30. https://doi.org/10.1176/appi.ajp.2012.12010112.CrossRefPubMedPubMedCentral

40.

Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27. https://doi.org/10.1001/archpsyc.62.6.617.CrossRefPubMedPubMedCentral

41.

Cadet JL. Epigenetics of stress, addiction, and resilience: therapeutic implications. Mol Neurobiol. 2016;53(1):545–60. https://doi.org/10.1007/s12035-014-9040-y.CrossRefPubMed

42.

Ungar M, Theron L. Resilience and mental health: how multisystemic processes contribute to positive outcomes. Lancet Psychiatry. 2020;7(5):441–8. https://doi.org/10.1016/S2215-0366(19)30434-1.CrossRefPubMed

43.

Davydov DM, Stewart R, Ritchie K, Chaudieu I. Resilience and mental health. Clin Psychol Rev. 2010;30(5):479–95. https://doi.org/10.1016/j.cpr.2010.03.003.CrossRefPubMed

44.

Chandra A, Acosta JD, Meredith LS, Sanches K, Howard S, Uscher-Pines L, et al. Understanding community resilience in the context of national health security: A literature review: RAND Corporation; 2010. https://www.rand.org/pubs/working_papers/WR737.html.

45.

Chandra A, Acosta J, Howard S, Uscher-Pines L, Williams M, Yeung D, et al. Building community resilience to disasters: a way forward to enhance National Health Security. Rand Health Q. 2011;1(1):6.PubMedPubMedCentral

46.

Moreno C, Wykes T, Galderisi S, Nordentoft M, Crossley N, Jones N, et al. How mental health care should change as a consequence of the COVID-19 pandemic. The Lancet Psychiatry. 2020;7(9):813–24. https://doi.org/10.1016/S2215-0366(20)30307-2.CrossRefPubMedPubMedCentral

47.

Morton MJ, Lurie N. Community resilience and public health practice. Am J Public Health. 2013;103(7):1158–60. https://doi.org/10.2105/AJPH.2013.301354.CrossRefPubMedPubMedCentral

48.

Dale SK, Bogart LM, Wagner GJ, Galvan FH, Klein DJ. Medical mistrust is related to lower longitudinal medication adherence among African-American males with HIV. J Health Psychol. 2014;21(7):1311–21. https://doi.org/10.1177/1359105314551950.CrossRefPubMedPubMedCentral

49.

Koch JW. Racial minorities’ trust in government and government decisionmakers. Soc Sci Q. 2019;100(1):19–37. https://doi.org/10.1111/ssqu.12548.CrossRef

50.

Shoff C, Yang T-C. Untangling the associations among distrust, race, and neighborhood social environment: a social disorganization perspective. Soc Sci Med. 2012;74(9):1342–52. https://doi.org/10.1016/j.socscimed.2012.01.012.CrossRefPubMedPubMedCentral

51.

Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. HIV Surveillance Supplemental Report [Internet]. 2020 May 2020; 25. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.

Titel: Resilience, Anxiety, Stress, and Substance Use Patterns During COVID-19 Pandemic in the Miami Adult Studies on HIV (MASH) Cohort
verfasst von: Janet Diaz-Martinez
Javier A. Tamargo
Ivan Delgado-Enciso
Qingyun Liu
Leonardo Acuña
Eduardo Laverde
Manuel A. Barbieri
Mary Jo Trepka
Adriana Campa
Suzanne Siminski
Pamina M. Gorbach
Marianna K. Baum
Publikationsdatum: 19.05.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: AIDS and Behavior / Ausgabe 11/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-021-03292-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Resilience, Anxiety, Stress, and Substance Use Patterns During COVID-19 Pandemic in the Miami Adult Studies on HIV (MASH) Cohort

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2021

Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers

HIV Treatment Cascade and PrEP Care Continuum Among Serodiscordant Male Couples in the United States

Cannabis and Alcohol Co-Use and Condomless Anal Sex Among Men Who have Sex with Men Living with HIV: An Event-Level Analysis

Navigating Stigma Trajectory and Mental Health Among Young Adults Living with Perinatal HIV in New York City

PositiveLinks and the COVID-19 Response: Importance of Low-Barrier Messaging for PLWH in Non-urban Virginia in a Crisis

Alarmingly High HIV Prevalence Among Adolescent and Young Men Who have Sex with Men (MSM) in Urban Indonesia

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin